Mohammad Arabi

Dr. Mohammad Arabi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KBKhalid I Bzeizi
Khalid I Bzeizi
MAMohammad Arabi
Mohammad Arabi
NJNegar Jamshidi
Negar Jamshidi
AAAli Hussain Albenmousa
Ali Hussain Albenmousa
FSFaisal M Sanai Faisal M Sanai
Faisal M Sanai Faisal M Sanai
SASaleh Alqahtani
Saleh Alqahtani
Hepatocellular carcinoma (HCC) occurs in nearly three-quarters of all primary liver cancers, with the majority not amenable to curative therapies. We therefore aimed to re-evaluate the safety, efficacy, and survival benefits of treating patients with drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) compared to the conventional transcatheter arterial chemoembolization (C-TACE). Several databases were searched with a strict eligibility criterion for studies reporting on adult patients with unresectable or recurrent HCC. The pooled analysis included 34 studies involving 4841 HCC patients with a median follow-up of 1.5 to 18 months. There were no significant differences between DEB-TACE and C-TACE with regard to complete response, partial response and disease stability. However, disease control (OR: 1.42 (95% CI (1.03,1.96) and objective response (OR: 1.33 (95% CI (0.99, 1.79) were significantly more effective for DEB-TACE treatment with fewer severe complications and all-cause mortality. The pooled-analysis did not find superiority of DEB-TACE in complete or partial response, disease stability, controlling disease progression, and 30 day or end-mortality. However, results showed that DEB-TACE is associated with a better objective response, disease control, and lower all-cause mortality with severe complications compared to C-TACE treatment. Given that the safety outcomes are based on limited studies with a potential for bias, there was no clear improvement of DEB-TACE over C-TACE treatment.

16 December 2015 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
MAMohammad Arabi
Mohammad Arabi
IAIshtiaq Ahmed
Ishtiaq Ahmed
AMAbdulaziz Mat’hami
Abdulaziz Mat’hami
Dildar AhmedDildar Ahmed
Dildar Ahmed
NANaveed Aslam
Naveed Aslam

1 January 2015 in Saudi Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
MAMohammad Arabi
Mohammad Arabi
ABAli BenMousa
Ali BenMousa
KBKhaled Bzeizi
Khaled Bzeizi
FGFares Garad
Fares Garad
IAIshtiaq Ahmed
Ishtiaq Ahmed
MAMelfi Al-Otaibi
Melfi Al-Otaibi
Background/Aims: To compare the efficacy and safety profile of doxorubicin-loaded drug-eluting beads (DEB) to the conventional TACE (C-TACE) in the management of nonresectable hepatocellular carcinoma (HCC). Patients and Methods: All patients with nonresectable HCC who underwent either c-TACE or DEB-TACE during the period 2006–2014 and fulfilled the inclusion criteria were included in this retrospective study. Primary endpoints were tumor response rate at first imaging follow up, treatment-related liver toxicity, and treatment emergent adverse events (TEAE). Results: Thirty-five patients (51 procedures) in the DEB-TACE group and 19 patients (25 procedures) in the c-TACE group were included in the analysis. The median follow up time was 61 days (range 24– 538 days) in the DEB-TACE group and 86 days (range 3– 152 days) for the c-TACE group patients. Complete response (CR), objective response (OR), disease control (DC), and progressive disease (PD) rates were 11%, 24%, 17%, and 47%, respectively, in the DEB = TACE group compared with 4%, 32%, 28%, and 36%, respectively, in the c-TACE group. Mean ALT change from baseline was minimal in the DEB-TACE patients compared with c-TACE group (7.2 vs 79.4 units, P = 0.001). Hospital stay was significantly shorter in the DEB-TACE group (7.8 days vs 11.4 days; P = 0.038). The 2-year survival rate was 60% for the c-TACE patients and 58% for the DEB-TACE (P = 0.4). Conclusions: DEB-TACE compared with c-TACE is associated with lesser liver toxicity benefit, better tolerance, and shorter hospital stay. The two modalities however had similar survival and efficacy benefits.

30 July 2015 in Indian Journal of Radiology and Imaging
Verified
Journal Article
Open access
MAMohammad Arabi
Mohammad Arabi
VKVenkataramu Krishnamurthy
Venkataramu Krishnamurthy
WCWojciech Cwikiel
Wojciech Cwikiel
RVRanjith Vellody
Ranjith Vellody
TWThomas W Wakefield
Thomas W Wakefield
DWDavid Williams
David Williams
Purpose: To present the techniques for endovascular treatment of thrombosed filter-bearing inferior vena cavae (IVCs), along with short-term clinical and imaging follow-up. Materials and Methods: A total of 45 consecutive patients (17 females and 28 males), aged 19-79 years (mean age of 49 years), who had IVC filter placement complicated by symptomatic acute or chronic iliocaval thrombosis and underwent endovascular therapy were studied. All patients presented with lower extremity swelling and/or pain. One patient also had bilateral lower extremity swelling and chronic gastrointestinal (GI) bleeding which was secondary to chronic systemic to portal venous collaterals. Patients underwent one or more of the following endovascular treatments depending on the chronicity and extent of thrombosis: (a) catheter-directed thrombolysis (CDT) (n = 25), (b) pharmacomechanical thrombolysis (PMT) (n = 15), (c) balloon angioplasty (n = 45), and/or (d) stent placement across the filter (n = 42). In addition, 16 patients underwent groin arteriovenous fistula (AVF) creation (36%) and 3 (7%) had femoral venous thrombectomy to improve flow in the recanalized iliac veins and IVCs. Results: Anatomical success was achieved in all patients. Follow-up was not available in 10 patients (lost to follow-up, n = 4; expired due to comorbidities, n = 2; lost to follow-up after re-intervention, n = 4). At a mean follow-up time of 13.3 months (range 1-48 months), clinical success was achieved in 27 patients (60%), i.e. in 21 patients without re-intervention and in 6 patients with re-intervention. Clinical success was not achieved despite re-intervention in eight patients. Higher clinical success was noted in patients who did not require repeat interventions (P = 0.03) and the time to re-intervention was significantly shorter in patients who had clinical failure (P = 0.01). AVF creation did not improve the clinical success rate (P = 1). There was no significant difference in clinical success between patients who had acute or subacute thrombosis compared to those who had chronically occluded filter-bearing IVCs (P = 1). Conclusion: This study suggests that endovascular therapy for thrombosed filter-bearing IVCs is safe and technically feasible.

1 September 2011 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
KWKa Kit Wong
Ka Kit Wong
MAMohammad Arabi
Mohammad Arabi
IZImene Zerizer
Imene Zerizer
AAAdil Al-Nahhas
Adil Al-Nahhas
DRDomenico Rubello
Domenico Rubello
MGMilton D. Gross
Milton D. Gross
Positron emission tomography (PET) has seen an increasing clinical utilization in the last decade, such that it is now a standard oncology imaging modality. Its success is based on the detection of altered fluorine-18 fluorodeoxyglucose (18F-FDG) biodistribution, reflecting glucose transport/metabolism in malignant tumor tissues. Integrated PET/computed tomography cameras combine functional and anatomical information in a synergistic manner that improves diagnostic interpretation, and newer positron-emitting radiopharmaceuticals have been developed to expand the application of non-FDG PET imaging. The increasing use of cross-sectional imaging procedures has led to a more frequent detection of incidental adrenal masses. Although conventional imaging modalities such as computed tomography and MRI can characterize the majority of these lesions, 18F-FDG PET has been reported as a useful tool to distinguish benign from malignant etiologies in indeterminate adrenal masses. Although 18F-FDG PET has enjoyed success in staging a wide range of cancers, including detection of adrenal metastases and evaluation of adrenocortical carcinoma, it has had limited impact for the evaluation of neuroendocrine tumors. Positron-emitting amine precursor and somatostatin analogs have been validated in research settings to provide accurate imaging of enterochromaffin and chromaffin neuroendocrine tumors and medullary thyroid cancer. The aim of this review article is to provide an overview of the role of 18F-FDG and newer positron-emitting radiopharmaceuticals in the evaluation of adrenal and neuroendocrine tumors.

1 December 2016 in Saudi Medical Journal
Verified
Journal Article
Open access
PDF file
NGNoha Husain Guzaiz
Noha Husain Guzaiz
MAMohammad Arabi
Mohammad Arabi
AKAzzam Khankan
Azzam Khankan
RSRefaat Salman
Refaat Salman
MAMohammed Al-Toki
Mohammed Al-Toki
MAMohammad Al-Moaiqel
Mohammad Al-Moaiqel
Gastroesophageal stenting for the management of post sleeve gastrectomy leak. A single institution experience